• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2007-2018 年中国广东女性人群宫颈人乳头瘤病毒感染、持续感染和清除的回顾性队列研究。

Incidence, persistence and clearance of cervical human papillomavirus among women in Guangdong, China 2007-2018: A retrospective cohort study.

机构信息

School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, PR China.

Department of Gynecology, Guangdong Provincial Women and Children Hospital, Guangzhou, PR China.

出版信息

J Infect Public Health. 2021 Jan;14(1):42-49. doi: 10.1016/j.jiph.2020.11.011. Epub 2020 Dec 17.

DOI:10.1016/j.jiph.2020.11.011
PMID:33341483
Abstract

BACKGROUND

Previous studies showed the incidence, persistence and clearance of cervical human papillomavirus (HPV) among women varies from regions. There is no study on dynamic changes of HPV infection among women in Guangdong.

METHODS

It is a retrospective cohort study that included gynecological outpatients aged ≥15 years and retested for HPV within 24 months in Guangdong Women and Children Hospital to estimate HPV incidence, persistence and clearance. Outcomes were estimated through the proportion of HPV incidence, persistence and clearance in HPV-negative or HPV-positive women. Moreover, we examined HPV incidence, persistence and clearance among women who retested in four calendar periods: 0-6, 6-12, 12-18, 18-24 months after the first test.

RESULTS

33,328 gynecological outpatients were included in our study. Incidence rates of any HPV, high-risk (HR) HPV and low-risk (LR) HPV were 10.58%, 8.68% and 4.83%. The most common incident HR HPV were HPV52 (2.69%), HPV16 (1.23%) and HPV58 (1.23%). Persistence rates of any HPV, HR HPV and LR HPV were 47.55%, 42.77% and 33.88%. HPV52 (42.33%), HPV58 (40.74%) and HPV68 (32.36%) were commonly found persistent types. And clearance rates of any HPV, HR HPV and LR HPV were 52.44%, 57.23% and 66.12%.The lowest clearance rates were observed for HPV52 (57.67%), HPV68 (67.64%) and HPV39 (68.56%). HPV incidence and persistence were higher among women aged 15-19 years and ≥55 years. HPV incidence and persistence were found higher among women who retested within 6 months than others in other periods.

CONCLUSIONS

HPV52, 58, 68, and 39 were the more likely to cause incident and persistent infection, and less likely to be cleared among women in Guangdong. HPV incidence and persistent infection were higher among women aged both younger and older women compared to middle aged women. HPV retesting period may impact the detection of HPV incidence, persistence and clearance.

摘要

背景

先前的研究表明,女性中宫颈人乳头瘤病毒(HPV)的发病率、持续性和清除率因地区而异。目前尚无关于广东女性 HPV 感染动态变化的研究。

方法

这是一项回顾性队列研究,纳入了广东省妇幼保健院年龄≥15 岁的妇科门诊患者,并在 24 个月内对其进行了 HPV 复查,以估计 HPV 阴性或 HPV 阳性女性的 HPV 发病率、持续性和清除率。通过 HPV 阴性或 HPV 阳性女性中 HPV 发病率、持续性和清除率的比例来评估结果。此外,我们检查了在首次检测后 0-6、6-12、12-18 和 18-24 个月四个日历期间复查的女性中 HPV 的发病率、持续性和清除率。

结果

本研究纳入了 33328 名妇科门诊患者。任何 HPV、高危型(HR)HPV 和低危型(LR)HPV 的发病率分别为 10.58%、8.68%和 4.83%。最常见的新发 HR-HPV 为 HPV52(2.69%)、HPV16(1.23%)和 HPV58(1.23%)。任何 HPV、HR-HPV 和 LR-HPV 的持续性分别为 47.55%、42.77%和 33.88%。HPV52(42.33%)、HPV58(40.74%)和 HPV68(32.36%)是常见的持续性 HPV 类型。任何 HPV、HR-HPV 和 LR-HPV 的清除率分别为 52.44%、57.23%和 66.12%。HPV52(57.67%)、HPV68(67.64%)和 HPV39(68.56%)的清除率最低。15-19 岁和≥55 岁的女性 HPV 发病率和持续性更高。与其他时期相比,6 个月内复查的女性 HPV 发病率和持续性更高。

结论

HPV52、58、68 和 39 更有可能导致新发和持续性感染,且在广东女性中更不容易清除。与中年女性相比,年轻和年老女性的 HPV 发病率和持续性感染更高。HPV 复查时间可能会影响 HPV 发病率、持续性和清除率的检测。

相似文献

1
Incidence, persistence and clearance of cervical human papillomavirus among women in Guangdong, China 2007-2018: A retrospective cohort study.2007-2018 年中国广东女性人群宫颈人乳头瘤病毒感染、持续感染和清除的回顾性队列研究。
J Infect Public Health. 2021 Jan;14(1):42-49. doi: 10.1016/j.jiph.2020.11.011. Epub 2020 Dec 17.
2
Prevalence and distribution of human papillomavirus (HPV) in Luoyang city of Henan province during 2015-2021 and the genetic variability of HPV16 and 52.2015-2021 年河南省洛阳市人乳头瘤病毒(HPV)的流行状况及分布情况和 HPV16、52 的基因变异。
Virol J. 2022 Mar 4;19(1):37. doi: 10.1186/s12985-022-01759-5.
3
Epidemiology of human papillomavirus infection in women from Xiamen, China, 2013 to 2023.中国厦门地区女性人群人乳头瘤病毒感染的流行病学研究,2013 年至 2023 年。
Front Public Health. 2024 Mar 21;12:1332696. doi: 10.3389/fpubh.2024.1332696. eCollection 2024.
4
The prevalence of human papillomavirus among women in northern Guangdong Province of China.中国广东省北部地区女性中人类乳头瘤病毒的流行情况。
Sci Rep. 2022 Aug 3;12(1):13353. doi: 10.1038/s41598-022-17632-y.
5
Characteristics of women infected with human papillomavirus in a tertiary hospital in Beijing China, 2014-2018.2014-2018 年中国北京一家三甲医院感染人乳头瘤病毒的女性特征。
BMC Infect Dis. 2019 Jul 29;19(1):670. doi: 10.1186/s12879-019-4313-8.
6
Prevalence and genotype distribution of human papillomavirus infection among female outpatients in Northeast China: a population-based survey of 110,927 women.中国东北地区女性门诊患者人乳头瘤病毒感染的患病率及基因型分布:一项基于110,927名女性的人群调查
Arch Gynecol Obstet. 2023 Jul;308(1):35-41. doi: 10.1007/s00404-022-06653-7. Epub 2022 Jul 29.
7
Prevalence and genotype distribution of human papillomavirus infection among women in Jingzhou, China: a population-based study of 51,720 women.中国荆州地区女性人群人乳头瘤病毒感染的流行率及基因型分布:一项基于人群的 51720 例女性研究。
Virol J. 2023 Dec 15;20(1):297. doi: 10.1186/s12985-023-02262-1.
8
Prevalent characteristics of human papillomavirus infection in 29,508 women in Jinshan District, Shanghai.上海市金山区29508名女性人乳头瘤病毒感染的流行特征
Taiwan J Obstet Gynecol. 2022 Nov;61(6):971-976. doi: 10.1016/j.tjog.2022.07.007.
9
Type-specific persistence and associated risk factors of human papillomavirus infections in women living in central Italy.意大利中部地区女性人群中 HPV 感染的型别特异性持续性及其相关危险因素。
Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):222-6. doi: 10.1016/j.ejogrb.2013.01.012. Epub 2013 Feb 8.
10
Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study.细胞学正常女性中宫颈人乳头瘤病毒感染的患病率、感染情况及清除情况:夏威夷人乳头瘤病毒队列研究
Cancer Res. 2008 Nov 1;68(21):8813-24. doi: 10.1158/0008-5472.CAN-08-1380.

引用本文的文献

1
Epidemiological characteristics of human papillomavirus in Guangzhou, China-A retrospective analysis of 76,898 cases.中国广州人乳头瘤病毒的流行病学特征——76898例病例的回顾性分析
BMC Public Health. 2025 Jun 3;25(1):2061. doi: 10.1186/s12889-025-23264-4.
2
Overcoming Barriers to Human Papillomavirus Vaccination in Guangdong Province, China.克服中国广东省人乳头瘤病毒疫苗接种的障碍。
Vaccines (Basel). 2025 Apr 29;13(5):482. doi: 10.3390/vaccines13050482.
3
Persistence and clearance rates of human papillomaviruses in a cohort of women treated or not treated for cervical dysplasia in northwest Ethiopia.
埃塞俄比亚西北部一组接受或未接受宫颈发育异常治疗的女性中人乳头瘤病毒的持续感染率和清除率
Sci Rep. 2025 Mar 10;15(1):8218. doi: 10.1038/s41598-025-87568-6.
4
Global pattern of persistent human papillomavirus infection in female genital tract: An update system review and meta-analysis.女性生殖道持续性人乳头瘤病毒感染的全球模式:一项更新的系统评价和荟萃分析。
iScience. 2024 Sep 19;27(10):110991. doi: 10.1016/j.isci.2024.110991. eCollection 2024 Oct 18.
5
Influence of COVID-19 pandemic on prevalence and genotype distribution of HPV in cervical cancer screening population.COVID-19 大流行对宫颈癌筛查人群中 HPV 感染率和基因型分布的影响。
Virol J. 2024 Oct 23;21(1):261. doi: 10.1186/s12985-024-02497-6.
6
Prevalence of human papillomavirus and cervical lesions among elderly women: an unignored challenge to cervical cancer prevention.人乳头瘤病毒和宫颈病变在老年女性中的流行:宫颈癌预防中不容忽视的挑战。
Ann Med. 2024 Dec;56(1):2404548. doi: 10.1080/07853890.2024.2404548. Epub 2024 Sep 19.
7
Clinical efficacy of a new therapeutic option for lower genital tract lesions: 5-ALA photodynamic therapy.新型下生殖道病变治疗选择的临床疗效:5-ALA 光动力疗法。
Lasers Med Sci. 2024 Jul 5;39(1):172. doi: 10.1007/s10103-024-04129-5.
8
Characteristic of persistent human papillomavirus infection in women worldwide: a meta-analysis.全球女性持续性人乳头瘤病毒感染的特征:一项荟萃分析。
PeerJ. 2023 Nov 14;11:e16247. doi: 10.7717/peerj.16247. eCollection 2023.
9
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.异源加强免疫 PastoCovac Plus 对 ChAdOx1-S 或 BBIBP-CorV 初免个体的 COVID-19 免疫原性和安全性。
PLoS Pathog. 2023 Nov 1;19(11):e1011744. doi: 10.1371/journal.ppat.1011744. eCollection 2023 Nov.
10
Cervicovaginal Gardnerella sialidase-encoding gene in persistent human papillomavirus infection.持续性人乳头瘤病毒感染的宫颈阴道 Gardnerella 唾液酸酶编码基因。
Sci Rep. 2023 Aug 31;13(1):14266. doi: 10.1038/s41598-023-41469-8.